404 related articles for article (PubMed ID: 22688257)
21. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
Skírnisdóttir I; Seidal T
Int J Gynecol Cancer; 2011 Aug; 21(6):1024-31. PubMed ID: 21792012
[TBL] [Abstract][Full Text] [Related]
22. [Recent advances on ovarian epithelial cancer: definition, subtypes and pathologic features].
Guo DH; Zheng WX
Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):624-8. PubMed ID: 24314254
[No Abstract] [Full Text] [Related]
23. FGF18 as a potential biomarker in serous and mucinous ovarian tumors.
El-Gendi S; Abdelzaher E; Mostafa MF; Sheasha GA
Tumour Biol; 2016 Mar; 37(3):3173-83. PubMed ID: 26427667
[TBL] [Abstract][Full Text] [Related]
24. Pattern of HER-2 Gene Amplification and Protein Expression in Benign, Borderline, and Malignant Ovarian Serous and Mucinous Neoplasms.
Mohammed RAA; Makboul R; Elsers DAH; Elsaba TMAM; Thalab AMAB; Shaaban OM
Int J Gynecol Pathol; 2017 Jan; 36(1):50-57. PubMed ID: 27309616
[TBL] [Abstract][Full Text] [Related]
25. The immunohistochemical expression of p53 and Ki67 in ovarian epithelial borderline tumors. Correlation with clinicopathological factors.
Giurgea LN; Ungureanu C; Mihailovici MS
Rom J Morphol Embryol; 2012; 53(4):967-73. PubMed ID: 23303020
[TBL] [Abstract][Full Text] [Related]
26. Sox10 expression in ovarian epithelial tumors is associated with poor overall survival.
Kwon AY; Heo I; Lee HJ; Kim G; Kang H; Heo JH; Kim TH; An HJ
Virchows Arch; 2016 May; 468(5):597-605. PubMed ID: 26951260
[TBL] [Abstract][Full Text] [Related]
27. Survivin in ovary tumors.
Plewka D; Jakubiec-Bartnik B; Morek M; Bogunia E; Bienioszek M; Wolski H; Kotrych D; Dziekan K; Seremak-Mrozikiewicz A; Plewka A
Ginekol Pol; 2015 Jul; 86(7):525-30. PubMed ID: 26376531
[TBL] [Abstract][Full Text] [Related]
28. The O-Linked Glycome and Blood Group Antigens ABO on Mucin-Type Glycoproteins in Mucinous and Serous Epithelial Ovarian Tumors.
Vitiazeva V; Kattla JJ; Flowers SA; Lindén SK; Premaratne P; Weijdegård B; Sundfeldt K; Karlsson NG
PLoS One; 2015; 10(6):e0130197. PubMed ID: 26075384
[TBL] [Abstract][Full Text] [Related]
29. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
[TBL] [Abstract][Full Text] [Related]
30. Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary.
Kurokawa T; Yoshida Y; Kawahara K; Tsuchida T; Okazawa H; Fujibayashi Y; Yonekura Y; Kotsuji F
Int J Cancer; 2004 May; 109(6):926-32. PubMed ID: 15027127
[TBL] [Abstract][Full Text] [Related]
31. Expression of Lysine-specific demethylase 1 in human epithelial ovarian cancer.
Chen C; Ge J; Lu Q; Ping G; Yang C; Fang X
J Ovarian Res; 2015 May; 8():28. PubMed ID: 25956476
[TBL] [Abstract][Full Text] [Related]
32. Mucinous, endometrioid, and serous ovarian cancers with peritoneal dissemination are potent candidates for P-cadherin targeted therapy: a retrospective cohort study.
Kayahashi K; Mizumoto Y; Matsuoka A; Obata T; Iwadare J; Nakamura M; Daikoku T; Fujiwara H
BMC Cancer; 2021 Jan; 21(1):32. PubMed ID: 33413178
[TBL] [Abstract][Full Text] [Related]
33. Loss/Down-regulation of tumor suppressor in lung cancer 1 expression is associated with tumor progression and is a biomarker of poor prognosis in ovarian carcinoma.
Yang G; He W; Cai M; Luo F; Kung H; Guan X; Zeng Y; Xie D
Int J Gynecol Cancer; 2011 Apr; 21(3):486-93. PubMed ID: 21436696
[TBL] [Abstract][Full Text] [Related]
34. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
McCluggage WG
Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
[TBL] [Abstract][Full Text] [Related]
35. Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma.
Yokoyama Y; Charnock-Jones DS; Licence D; Yanaihara A; Hastings JM; Holland CM; Emoto M; Umemoto M; Sakamoto T; Sato S; Mizunuma H; Smith SK
Br J Cancer; 2003 Jan; 88(2):237-44. PubMed ID: 12610509
[TBL] [Abstract][Full Text] [Related]
36. Outcome in serous ovarian cancer is not associated with LATS expression.
Montavon C; Stricker GR; Schoetzau A; Heinzelmann-Schwarz V; Jacob F; Fedier A
J Cancer Res Clin Oncol; 2019 Nov; 145(11):2737-2749. PubMed ID: 31586262
[TBL] [Abstract][Full Text] [Related]
37. The expression of H3K9Ac, H3K14Ac, and H4K20TriMe in epithelial ovarian tumors and the clinical significance.
Zhen L; Gui-lan L; Ping Y; Jin H; Ya-li W
Int J Gynecol Cancer; 2010 Jan; 20(1):82-6. PubMed ID: 20057286
[TBL] [Abstract][Full Text] [Related]
38. Expression of HER2/neu, estrogen and progesterone receptors, CA 125 and CA19-9 on cancer cell membrane in patients with serous and mucinous carcinoma of the ovary.
Karaferic A; Jovanovic D; Jelic S
J BUON; 2009; 14(4):635-9. PubMed ID: 20148455
[TBL] [Abstract][Full Text] [Related]
39. Insulin-like growth factor-binding protein 2 and 5 are differentially regulated in ovarian cancer of different histologic types.
Wang H; Rosen DG; Wang H; Fuller GN; Zhang W; Liu J
Mod Pathol; 2006 Sep; 19(9):1149-56. PubMed ID: 16729015
[TBL] [Abstract][Full Text] [Related]
40. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
Mackenzie R; Kommoss S; Winterhoff BJ; Kipp BR; Garcia JJ; Voss J; Halling K; Karnezis A; Senz J; Yang W; Prigge ES; Reuschenbach M; Doeberitz MV; Gilks BC; Huntsman DG; Bakkum-Gamez J; McAlpine JN; Anglesio MS
BMC Cancer; 2015 May; 15():415. PubMed ID: 25986173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]